🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-521217-46-00
Authorised Phase IV

Impact of influenza vaccination on nasal resident memory immune responses and respiratory peripheral memory immune responses - MUCOVAC 2

2025-521217-46-00 · tracked via the Priya Life Science EU tracker
Sponsor
Centre Hospitalier Universitaire De Saint Etienne
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Virus Diseases
Decision date
02/12/2025
Enrollment target
30
Sites
France

Condition studied

Adults seeking active immunisation against the seasonal influenza virus

Investigational medicinal product(s)

Flucelvax suspension for injection in pre-filled syringe Influenza vaccine (surface antigeninactivatedprepared in cell cultures)VAXIGRIPTETRAsuspension injectable en seringue préremplie Vaccin grippal quadrivalent (inactivéà virion fragmenté)INFLUVAC TETRAsuspension injectable en seringue préremplie Vaccin grippal inactivé à antigènes de surface

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

Frequency of resident memory lymphocytes in the nasal mucosa and expression rate of migration markers towards the respiratory mucosa on peripheral memory lymphocytes before and after intramuscular influenza vaccination: variation in frequency between before and after vaccination

Endpoint detail

The frequencies of resident memory T and B lymphocytes in the nasal cavity and the percentage of migration markers specific to the respiratory mucosa expressed on peripheral memory T and B lymphocytes., Correlation coefficients between the frequency of nasal resident memory lymphocytes, the percentage of migration markers expressed on peripheral memory lymphocytes, as well as anti-Influenza titers and Influenza neutralising antibody titers in mucosa and serum, the systemic cellular response specific to Influenza and the percentage of expression of genes involved in the systemic immune response.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521217-46-00 on CTIS ↗ ← All trials in the EU